Low neuroleptic serum levels in patients receiving fluphenazine decanoate

L. E. Tune, I. Creese, J. T. Coyle, G. Pearlson, S. H. Snyder

    Research output: Contribution to journalArticlepeer-review

    Abstract

    The authors monitored serum levels of fluphenazine in nine patients following injections of fluphenazine decanoate ranging from 10 to 75 mg. Levels were detected by a radioreceptor assay based on the ability of the drug to compete with 3H-spiroperidol for binding to dopamine receptors in rat caudate membranes. Serum levels of fluphenazine were quite stable over a 2- to 3-week period following single intramuscular injections of the decanoate and correlated with injected dose. Following decanoate treatment serum levels of fluphenazine are substantially lower than levels observed for most other neuroleptics administered orally. This raises questions as to how fluphenazine decanoate can exert therapeutic actions.

    Original languageEnglish (US)
    Pages (from-to)80-82
    Number of pages3
    JournalAmerican Journal of Psychiatry
    Volume137
    Issue number1
    DOIs
    StatePublished - Jan 1 1980

    ASJC Scopus subject areas

    • Psychiatry and Mental health

    Fingerprint Dive into the research topics of 'Low neuroleptic serum levels in patients receiving fluphenazine decanoate'. Together they form a unique fingerprint.

    Cite this